WNK2 and prostate cancer: Preclinical studies demonstrated that inhibition of ligand-dependent heterodimerisation with pertuzumab effectively inhibits tumour growth and diminishes mitogen-activated protein kinase and phosphatidyl-inositol 3-kinase activity in both androgen-dependent and -independent prostate cancer xenograft models.